Alendronate Sodium
Product Images NDC 50090-4076

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 50090-4076). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 01

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 02

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 03

This appears to be a table or chart showing the increase in bone mineral density (BMD) in postmenopausal women with osteoporosis who received treatment with alendronate sodium at a dosage of 10 mg/day for three years. The BMD measurements were taken at the lumbar spine, femoral neck, and trochanter. Unfortunately, there is no usable text here to generate any descriptive information beyond this.*

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 04

Osteoporosis Treatment Studies in Postmenopausal women comparing the effect of Alendronate Sodium 10 mg/day versus Placebo over time on Lumbar Spine BMD percent change from baseline. The text includes data from a US and multinational study, with mean % change from baseline BMD at different time points (in months) presented graphically.*

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 05

This appears to be a table with headings related to BMD (Bone Mineral Density) and changes in BMD from baseline in osteoporosis prevention studies in postmenopausal women. There are also two columns indicating sodium intake. However, without more context or specific values, it is difficult to provide a more detailed description or analysis.*

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 06

This is a report on an increase in bone mineral density (BMD) after one year of treatment with Alendronate Sodium 5 mg/day in patients undergoing glucocorticoid therapy. The report includes measurements of BMD in the lumbar spine, femoral neck, and trochanter. The text also includes the name of a company, EZAvs, and the word "Multinacional", which means multinational in Spanish.*

FDA Label Image

1203dd0c 809a 4409 B948 B5e816b8a63a 07

This appears to be a table from a study comparing the effects of Alendronate Sodium 40 mg/day versus placebo or Etidronate 400 mg/day on serum alkaline phosphatase in patients with Paget's Disease of Bone. The table shows the mean percentage change from baseline in serum alkaline phosphatase levels over time, with results from a multinational and a US study. The study included 27 and 47 patients, respectively.*

FDA Label Image

Label Image (Lbl500904076)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.